Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free EKF Stock Alerts

EKF Diagnostics (EKF) Competitors

EKF Diagnostics logo
GBX 25 +0.10 (+0.40%)
As of 12:46 PM Eastern
Compare

EKF vs. NIOX, CREO, IUG, NCYT, and IHC

Should you buy EKF Diagnostics stock or one of its competitors? MarketBeat compares EKF Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with EKF Diagnostics include NIOX Group (NIOX), Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Novacyt (NCYT), and Inspiration Healthcare Group (IHC). These companies are all part of the "medical devices" industry.

How does EKF Diagnostics compare to NIOX Group?

EKF Diagnostics (LON:EKF) and NIOX Group (LON:NIOX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

EKF Diagnostics presently has a consensus target price of GBX 35, indicating a potential upside of 40.00%. NIOX Group has a consensus target price of GBX 86, indicating a potential upside of 43.80%. Given NIOX Group's higher possible upside, analysts clearly believe NIOX Group is more favorable than EKF Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
NIOX Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, EKF Diagnostics had 1 more articles in the media than NIOX Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for NIOX Group. EKF Diagnostics' average media sentiment score of 0.00 equaled NIOX Group'saverage media sentiment score.

Company Overall Sentiment
EKF Diagnostics Neutral
NIOX Group Neutral

22.2% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 7.6% of NIOX Group shares are owned by institutional investors. 39.9% of EKF Diagnostics shares are owned by company insiders. Comparatively, 5.1% of NIOX Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

NIOX Group has lower revenue, but higher earnings than EKF Diagnostics. NIOX Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.09£4.68M£0.4753.19
NIOX Group£48.70M5.17£995.88M£1.6436.47

EKF Diagnostics has a beta of 0.526, suggesting that its share price is 47% less volatile than the broader market. Comparatively, NIOX Group has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

NIOX Group has a net margin of 14.37% compared to EKF Diagnostics' net margin of 4.12%. NIOX Group's return on equity of 10.14% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
NIOX Group 14.37%10.14%3.95%

Summary

NIOX Group beats EKF Diagnostics on 7 of the 13 factors compared between the two stocks.

How does EKF Diagnostics compare to Creo Medical Group?

EKF Diagnostics (LON:EKF) and Creo Medical Group (LON:CREO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk, profitability and media sentiment.

In the previous week, EKF Diagnostics had 1 more articles in the media than Creo Medical Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Creo Medical Group. EKF Diagnostics' average media sentiment score of 0.00 equaled Creo Medical Group'saverage media sentiment score.

Company Overall Sentiment
EKF Diagnostics Neutral
Creo Medical Group Neutral

EKF Diagnostics has higher revenue and earnings than Creo Medical Group. Creo Medical Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.09£4.68M£0.4753.19
Creo Medical Group£6M10.77-£25.04M£1.0013.30

EKF Diagnostics currently has a consensus target price of GBX 35, indicating a potential upside of 40.00%. Creo Medical Group has a consensus target price of GBX 40, indicating a potential upside of 200.75%. Given Creo Medical Group's higher possible upside, analysts plainly believe Creo Medical Group is more favorable than EKF Diagnostics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Creo Medical Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

EKF Diagnostics has a beta of 0.526, indicating that its share price is 47% less volatile than the broader market. Comparatively, Creo Medical Group has a beta of 1.6246382, indicating that its share price is 62% more volatile than the broader market.

Creo Medical Group has a net margin of 88.33% compared to EKF Diagnostics' net margin of 4.12%. Creo Medical Group's return on equity of 9.56% beat EKF Diagnostics' return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
Creo Medical Group 88.33%9.56%-20.09%

22.2% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 44.1% of Creo Medical Group shares are owned by institutional investors. 39.9% of EKF Diagnostics shares are owned by insiders. Comparatively, 6.4% of Creo Medical Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

EKF Diagnostics beats Creo Medical Group on 8 of the 15 factors compared between the two stocks.

How does EKF Diagnostics compare to Intelligent Ultrasound Group?

EKF Diagnostics (LON:EKF) and Intelligent Ultrasound Group (LON:IUG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

EKF Diagnostics has a net margin of 4.12% compared to Intelligent Ultrasound Group's net margin of -23.11%. EKF Diagnostics' return on equity of 3.01% beat Intelligent Ultrasound Group's return on equity.

Company Net Margins Return on Equity Return on Assets
EKF Diagnostics4.12% 3.01% 5.27%
Intelligent Ultrasound Group -23.11%-23.58%-13.51%

In the previous week, EKF Diagnostics had 1 more articles in the media than Intelligent Ultrasound Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Intelligent Ultrasound Group. EKF Diagnostics' average media sentiment score of 0.00 equaled Intelligent Ultrasound Group'saverage media sentiment score.

Company Overall Sentiment
EKF Diagnostics Neutral
Intelligent Ultrasound Group Neutral

EKF Diagnostics presently has a consensus price target of GBX 35, indicating a potential upside of 40.00%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, equities analysts plainly believe EKF Diagnostics is more favorable than Intelligent Ultrasound Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Intelligent Ultrasound Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

EKF Diagnostics has a beta of 0.526, meaning that its share price is 47% less volatile than the broader market. Comparatively, Intelligent Ultrasound Group has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

22.2% of EKF Diagnostics shares are owned by institutional investors. Comparatively, 75.5% of Intelligent Ultrasound Group shares are owned by institutional investors. 39.9% of EKF Diagnostics shares are owned by insiders. Comparatively, 12.8% of Intelligent Ultrasound Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

EKF Diagnostics has higher revenue and earnings than Intelligent Ultrasound Group. Intelligent Ultrasound Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EKF Diagnostics£51.56M2.09£4.68M£0.4753.19
Intelligent Ultrasound Group£6.57M0.00-£2.27M-£0.68N/A

Summary

EKF Diagnostics beats Intelligent Ultrasound Group on 13 of the 14 factors compared between the two stocks.

How does EKF Diagnostics compare to Novacyt?

Novacyt (LON:NCYT) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

10.7% of Novacyt shares are held by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are held by institutional investors. 0.7% of Novacyt shares are held by company insiders. Comparatively, 39.9% of EKF Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

EKF Diagnostics has a consensus target price of GBX 35, suggesting a potential upside of 40.00%. Given EKF Diagnostics' stronger consensus rating and higher probable upside, analysts plainly believe EKF Diagnostics is more favorable than Novacyt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novacyt
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

EKF Diagnostics has a net margin of 4.12% compared to Novacyt's net margin of -135.96%. EKF Diagnostics' return on equity of 3.01% beat Novacyt's return on equity.

Company Net Margins Return on Equity Return on Assets
Novacyt-135.96% -121.30% -27.98%
EKF Diagnostics 4.12%3.01%5.27%

EKF Diagnostics has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novacyt£20.03M1.37-£36.80M-£32.00N/A
EKF Diagnostics£51.56M2.09£4.68M£0.4753.19

Novacyt has a beta of 0.973, meaning that its stock price is 3% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.526, meaning that its stock price is 47% less volatile than the broader market.

In the previous week, Novacyt and Novacyt both had 1 articles in the media. Novacyt's average media sentiment score of 0.75 beat EKF Diagnostics' score of 0.00 indicating that Novacyt is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novacyt
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
EKF Diagnostics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

EKF Diagnostics beats Novacyt on 13 of the 15 factors compared between the two stocks.

How does EKF Diagnostics compare to Inspiration Healthcare Group?

Inspiration Healthcare Group (LON:IHC) and EKF Diagnostics (LON:EKF) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

EKF Diagnostics has higher revenue and earnings than Inspiration Healthcare Group. Inspiration Healthcare Group is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspiration Healthcare Group£45.20M0.52-£12.20M-£13.65N/A
EKF Diagnostics£51.56M2.09£4.68M£0.4753.19

7.4% of Inspiration Healthcare Group shares are held by institutional investors. Comparatively, 22.2% of EKF Diagnostics shares are held by institutional investors. 8.4% of Inspiration Healthcare Group shares are held by insiders. Comparatively, 39.9% of EKF Diagnostics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

EKF Diagnostics has a net margin of 4.12% compared to Inspiration Healthcare Group's net margin of -25.32%. EKF Diagnostics' return on equity of 3.01% beat Inspiration Healthcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Inspiration Healthcare Group-25.32% -69.35% -3.47%
EKF Diagnostics 4.12%3.01%5.27%

In the previous week, EKF Diagnostics had 1 more articles in the media than Inspiration Healthcare Group. MarketBeat recorded 1 mentions for EKF Diagnostics and 0 mentions for Inspiration Healthcare Group. Inspiration Healthcare Group's average media sentiment score of 0.00 equaled EKF Diagnostics'average media sentiment score.

Company Overall Sentiment
Inspiration Healthcare Group Neutral
EKF Diagnostics Neutral

Inspiration Healthcare Group has a beta of 0.717, meaning that its stock price is 28% less volatile than the broader market. Comparatively, EKF Diagnostics has a beta of 0.526, meaning that its stock price is 47% less volatile than the broader market.

EKF Diagnostics has a consensus price target of GBX 35, suggesting a potential upside of 40.00%. Given EKF Diagnostics' stronger consensus rating and higher possible upside, analysts clearly believe EKF Diagnostics is more favorable than Inspiration Healthcare Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inspiration Healthcare Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
EKF Diagnostics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

EKF Diagnostics beats Inspiration Healthcare Group on 14 of the 15 factors compared between the two stocks.

Get EKF Diagnostics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EKF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EKF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EKF vs. The Competition

Export
MetricEKF DiagnosticsMedical Devices IndustryMedical SectorLON Exchange
Market Cap£107.63M£2.11B£6.68B£2.71B
Dividend Yield4.65%2.66%2.67%6.16%
P/E Ratio53.1914.7424.56366.28
Price / Sales2.09125.06566.6986,890.05
Price / Cash10.6415.9926.9927.85
Price / Book1.624.4610.527.71
Net Income£4.68M£144.75M£3.56B£5.89B
7 Day Performance-5.66%-1.28%-1.11%-0.75%
1 Month PerformanceN/A-3.00%1.28%1.84%
1 Year Performance-6.37%-1.64%21.20%71.71%

EKF Diagnostics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EKF
EKF Diagnostics
1.9429 of 5 stars		GBX 25
+0.4%		GBX 35
+40.0%		-3.9%£107.63M£51.56M53.19356
NIOX
NIOX Group
N/AGBX 59.80
-0.3%		GBX 86
+43.8%		-13.3%£251.68M£48.70M36.4692
CREO
Creo Medical Group
N/AGBX 13.25
-1.9%		GBX 40
+201.9%		-11.6%£64.37M£6M13.25279
IUG
Intelligent Ultrasound Group
N/AN/AN/AN/A£42.76M£6.57MN/A65
NCYT
Novacyt
N/AGBX 38.80
-1.8%		N/A-18.5%£28.11M£20.03MN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:EKF) was last updated on 6/9/2026 by MarketBeat.com Staff.
From Our Partners
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel